> Back to EJC

Recent editions

  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.
  • November 2015
    Caroline Robert on new developments in immunotherapy.
  • October 2015
    Milena Sant on the latest results from the EUROCARE study.
  • September 2015
    The science behind the IARC code that could reduce cancer in Europe.
  • July/August 2015
    Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
  • June 2015
    Lesley Seymour and Jan Bogaerts on the future of RECIST.
  • May 2015
    Paul Workman on strategies for overcoming resistance to new drugs.
  • April 2015
    Highlights from the TAT Congress in Paris.
  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – February 2016

Loading EJC News Focus video

Unravelling the mysteries of MDS

All cancers have some epigenetic component, but myelodysplastic syndromes (MDS) are the only diseases in which hypomethylating agents have had significant clinical activity. Colon cancer, for example has as much methylation as MDS but is resistant to these agents. Why that should be remains a mystery.

At the European Cancer Congress in Vienna (September 2015), Guillermo Garcia-Manero (MD Anderson Cancer Center, Houston, Texas) presented research into this and other difficult questions in MDS. In this EJC News Focus, he tells Helen Saul that the eventual answers could have implications in a wide range of cancers.